VANDA PHARMACEUTICALS INC (VNDA)
US9216591084 - Common Stock
Top movers in Wednesday's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Which stocks are experiencing notable movement on Wednesday?
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Why Vanda Pharmaceuticals Stock Is Skyrocketing Today
Future Pak wants Vanda, but Vanda doesn't want Future Pak.
Why Vanda Pharmaceuticals Stock Is Skyrocketing Today
Future Pak wants Vanda, but Vanda doesn't want Future Pak.
These stocks are gapping in today's session
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
Why Is Trio Petroleum (TPET) Stock Down 22% Today?
Trio Petroleum stock is falling on Wednesday as TPET investors learn of a securities purchase agreement and Senior Secured Note.
Why Is Trilogy Metals (TMQ) Stock Down 29% Today?
Trilogy Metals stock is falling on Wednesday as TMQ investors react to reports that the government plans to block its Ambler Access Project.
Why Is Vanda Pharmaceuticals (VNDA) Stock Up 34% Today?
Vanda Pharmaceuticals stock is heading higher on Wednesday as investors in VNDA learn of an acquisition offer for their shares.
Top movers in Wednesday's pre-market session
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Wednesday!
Commit To Purchase Vanda Pharmaceuticals At $3, Earn 18.9% Annualized Using Options
Notable Wednesday Option Activity: CBL, ARCB, VNDA
Which stocks are moving on Wednesday?
Let's take a look at the stocks that are in motion in today's session.
Discover the most active stocks in Wednesday's session. Stay informed about the stocks that are generating the most trading volume!
Which stocks are most active on Wednesday?
Which stocks are moving on Wednesday?
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
EDR Stock Alert: Endeavor Group Is Going Private for $13 Billion
Endeavor Group stock is on the move Wednesday as EDR holders react to news of Silver Lake taking the sports and entertainment company private.
These stocks are gapping in today's session
Gapping stocks in Wednesday's session
Costco Weight Loss Program: How You Can Get Ozempic From Costco
Costco is offering a new weight loss program for subscribers that may also include prescriptions for weight loss drug Ozempic.
Why Is Vanda Pharmaceuticals (VNDA) Stock Up 33% Today?
Vanda Pharmaceuticals stock is rising higher on Wednesday as investors in VNDA celebrate FDA approval of its bipolar treatment.
What's going on in today's pre-market session
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic this morning as we check out all of the biggest news worth reading about on Wednesday morning!
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Fanapt®...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceutical Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceutical Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceutical Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such...
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on March 4, 2024, it received a Complete Response Letter (CRL) from the...
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended...
Vanda updates on FDA review for Hetlioz label expansion (NASDAQ:VNDA)
Vanda Pharmaceuticals (VNDA) faces potential label expansion setbacks for sleep disorder therapy Hetlioz as the FDA cites deficiencies in its review. Read more here.
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2023 on...
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the United States District Court for the District of Columbia granted...
Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Patent and Trademark Office has issued a notice of allowance...
Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and Hepatology
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article titled "The Efficacy of Tradipitant in Patients...